Why Cathie Wood is confidently buying Genomics Stocks?
Cathie wood is one of the most influential investors of this decade. She is very much confident about her investing decisions and the moves she makes. Lately, she has been very much emphasizing genomics stocks. If you take a deeper look cathie wood stocks portfolio, there is a company called CRISPR Therapeutics which constitutes 3.6% of cathie wood portfolio and it is number 5th on her stocks list. She has 10.4 million units of CRISPR shares which have a current value of $1.68B.
Wondering what this company is about and why cathie wood has hugely invested in it?
Before going any further, first, let’s understand what this company does. CRISPR Therapeutics deals with something called genomics which is a study of genomes that is used to cure genetically inherited diseases.
Let’s first understand, what genomes are?
Genomes are a complete set of DNA that studies every single gene available in a living organism. Studying only genes is not sufficient for tracking down cures for many serious diseases. It is possible to find a cure for serious diseases using something called gene- editing.
Interest of investors in genomics in past 90 days
Genomic Revolution Aims to provide exposure to DNA sequencing technology, gene editing, CRISPR, therapeutics, agricultural biology, and molecular diagnostics. These innovations can help us restructuring health care, agriculture, pharmaceuticals, and enhancing the quality of life.Source: Ark Investment
Now let’s understand why Cathie wood has invested a massive chunk into genomics stock and why she is very confident regarding the genomics company’s growth?
Cathie has a massive investment in genomics stocks such as CRISPR because she believes that these companies have a very unique purpose that is curing impossible diseases such as Cancer and Diabetes. Diabetes is one of the most common diseases among older people and thus creating a huge market for business, and this is why Cathie wood has invested in companies dealing with DNA-sequencing, gene-editing, and gene therapy which could potentially find a cure for these long term diseases. She believes this stock will grow exponentially once they innovate the genomics space.